Status
Conditions
Treatments
About
This study employs novel methods to identify key determinants and consequences of concurrent HIV infection and regular cannabis use. This study will acquire extensive phenotype data from peripheral and brain markers of immune activation, brain structure, and neuropsychological performance (NP) in persons living with HIV (PLWH) receiving combination anti-retroviral therapy (cART) (80 regular cannabis users and 80 non-users) and HIV uninfected (HIV-) controls (80 regular cannabis users and 80 non-users). This study will provide key insights into the effects of regular cannabis and HIV on peripheral and brain markers of immune function and NP in PLWH and HIV- controls. These insights are critical for cure strategies and ongoing HIV treatment initiatives.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
320 participants in 4 patient groups
Loading...
Central trial contact
Elizabeth Westerhaus, MA; Linet Lopez
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal